top of page

About Our Team

Applying breakthrough science to develop innovative, clinically-impactful vaccines for people in need around the world

Matrivax is a biotechnology company developing human vaccines for the prevention and treatment of life-threatening infectious diseases.


Our pipeline includes two vaccine candidates implementing proprietary protective antigens against Streptococcus pneumoniae (MVX01) and Clostridioides difficile (MVX02).


Matrivax is a privately-held company funded by Morningside Investments and based in the biotech hub of Boston, MA.

Our Leadership

EM Vivid Oct_edited_edited_edited.jpg

Enda Moran, PhD, MBA

Chief Executive Officer

Kevin Killeen_2020-0903_edited_edited_ed

Kevin P. Killeen, PhD

Chief Scientific Officer

Matthew Copeland photo 10-20_edited_edited.jpg

Matt Copeland, MBA

Vice President, Finance

Schlegel-Outlook - 1 of 1.jpg

Jennifer D. Schlegel, PhD

Senior Director, CMC

bottom of page